pI: 4.5359 |
Length (AA): 439 |
MW (Da): 48868 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 437 | 5uuu (A) | 168 | 533 | 24.00 | 0 | 1 | 0.921468 | 0.73 |
31 | 405 | 4zzn (A) | 20 | 343 | 28.00 | 0 | 1 | 1.01676 | 0.13 |
167 | 223 | 5e8v (A) | 354 | 414 | 42.00 | 0.27 | 0.94 | 0.451437 | 0.74 |
178 | 289 | 5hvj (A) | 451 | 543 | 46.00 | 0.2 | 0.32 | 0.0750078 | 0.84 |
225 | 381 | 2i6l (B) | 148 | 318 | 25.00 | 0 | 0.63 | 0.689947 | -0.83 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_145920)
Species | Accession | Gene Product |
---|---|---|
Leishmania braziliensis | LbrM.17.0900 | protein kinase |
Leishmania donovani | LdBPK_301780.1 | protein kinase, putative |
Leishmania infantum | LinJ.30.1780 | protein kinase, putative |
Leishmania major | LmjF.30.1780 | protein kinase, putative |
Leishmania mexicana | LmxM.29.1780 | protein kinase, putative |
Trypanosoma brucei gambiense | Tbg972.6.2900 | protein kinase, putative |
Trypanosoma brucei | Tb927.6.3110 | cdc2-related protein kinase 11, putative |
Trypanosoma congolense | TcIL3000_0_50900 | protein kinase, putative |
Trypanosoma congolense | TcIL3000_6_2660 | protein kinase, putative |
Trypanosoma cruzi | TcCLB.511751.50 | cdc2-related protein kinase 11, putative |
Trypanosoma cruzi | TcCLB.507023.180 | cdc2-related protein kinase 11, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.3110 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.3110 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.3110 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.6.3110 this record | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.4
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Bos taurus | Glycogen synthase kinase-3 beta splice variant X1 | 419 aa | 24.9% | 385 aa | Compounds | References |
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 27.5% | 353 aa | Compounds | References |
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 28.1% | 349 aa | Compounds | References |
Patiria pectinifera | Cdc2 | 300 aa | 28.0% | 346 aa | Compounds | References |
Rattus norvegicus | Glycogen synthase kinase-3 beta | 420 aa | 24.7% | 385 aa | Compounds | References |
Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 28.4% | 348 aa | Compounds | References |
Rattus norvegicus | Mitogen-activated protein kinase 1 | 358 aa | 26.6% | 391 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 28.3% | 350 aa | Compounds | References |
Sus scrofa | Glycogen synthase kinase 3 beta | 420 aa | 24.9% | 385 aa | Compounds | References |
Rattus norvegicus | Mitogen-activated protein kinase 8 | 411 aa | 25.1% | 359 aa | Compounds | References |
27 literature references were collected for this gene.